Chimeric Antigen Receptor (CAR) T‑Cell​

Overview

Cancer Immunotherapy has been hailed as the ‘fifth pillar’ of cancer treatment. At the forefront of this ‘fifth pillar’ is CAR T-Cell Immunotherapy, which is personalised to each patient using their own T-Cells. CAR T-Cell Immunotherapy aims to improve the immune system’s intrinsic capabilities to identify and attack cancer cells while leaving healthy cells undamaged.

Chimeric

The CAR protein is ‘chimeric’ as it is engineered to have receptors to target cancer cells, which T-cells do not naturally possess.

Antigens

Antigens are proteins on the cancer cells which T-cells are engineered to target and bind to.

Receptor

The CAR protein that is added to the surface of the T-cells functions as a receptor to match antigen on cancer cells and destroy them.

T-Cells

The core of CAR T-cell Immunotherapy. T-cells are immune cells which are derived from patient’s own blood.

How Does CAR T-Cell Immunotherapy Work?

Advisory On Possible Side Effects

• Cytopenia

Blood consists of red blood cells, which carry oxygen and nutrients around the body, and white blood cells, which fight infection. Cytopenia occurs when the levels of one of these types of blood cells falls abnormally low.

• B-Cell Aplasia

B-Cell aplasia occurs when anti-CD19 CAR T-Cells kill normal B lymphocytes that express CD19. These patients are typically at high risk of developing infections, because of their hypogammaglobulinemia. However, this can be treated with intravenous immunoglobulin (IVIG) replacement therapy.

• Cytokine Release Syndrome

Potentially life-threatening condition that results from the pathologic over-activation of T-Cells. It is an acute systemic inflammatory syndrome characterised by fever and multiple organ dysfunction.

• Neurotoxicity

Damage to the brain or peripheral nervous system caused by exposure to natural or man-made toxic substances. These toxins can alter the activity of the nervous system in ways that can disrupt or kill nerves.

CAR T-Cell Immunotherapy Has Shown Some Incredible Promise In The Fight Against Cancer

Improve

Improve the patient’s immune system to search, identify and destroy cancer cells.

Reduce

Reduce the patient’s time under treatment.

Recover

Recover faster in comparison to conventional cancer treatments.

Lessen

Lessen the side effects from cancer treatment.

Remain

Remain in remission as CAR T-Cells may persist in the body after therapy.

Various Cancers Targeted With MGRC’s Immunotherapy Products

CAR-T FOR SOLID CANCERS

• Mesothelioma
• Glioma / Glioblastoma Multiforme
• Gastric Cancer
• Pancreatic Cancer
• Melanoma / Skin Cancer
• Ovarian Cancer
• HPV Associated Cancer

CAR-T FOR LIQUID CANCERS

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Chronic lymphocytic leukemia (CLL)
• Chronic myeloid leukemia (CML)
• Hodgkin lymphoma (HL)
• Non-Hodgkin lymphoma (NHL)
• Multiple myeloma
• Plasmacytoma